These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 33455091)

  • 1. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer.
    Maeda H; Takeda K; Urushihara H; Kurokawa T
    Cancer Rep (Hoboken); 2021 Jun; 4(3):e1334. PubMed ID: 33455091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial.
    Martini A; Pfail J; Montorsi F; Galsky MD; Oh WK
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):638-645. PubMed ID: 32313142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data.
    Fizazi K; Le Maitre A; Hudes G; Berry WR; Kelly WK; Eymard JC; Logothetis CJ; Pignon JP; Michiels S;
    Lancet Oncol; 2007 Nov; 8(11):994-1000. PubMed ID: 17942366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer.
    Sonpavde G; Pond GR; Armstrong AJ; Galsky MD; Leopold L; Wood BA; Wang SL; Paolini J; Chen I; Chow-Maneval E; Mooney DJ; Lechuga M; Smith MR; Michaelson MD
    BJU Int; 2014 Dec; 114(6b):E25-E31. PubMed ID: 24298897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of potential surrogate endpoints for prediction of overall survival in patients with castration-resistant prostate cancer: trial-level meta-analysis.
    Chen W; Li L; Ji S; Song X; Lu W; Zhou T
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1521-1532. PubMed ID: 31463577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial Level Analysis of Prostate-Specific Antigen-Related Versus Unrelated Endpoints in Phase III Trials of First-Line and Second-Line Medical Treatments of Patients With Metastatic Castration-Resistant Prostate Cancer.
    Colloca G; Vitucci P; Venturino A
    Clin Genitourin Cancer; 2016 Oct; 14(5):389-397. PubMed ID: 27108003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
    Li L; Pan Z
    Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety comparison of docetaxel, cabazitaxel, estramustine, and mitoxantrone for castration-resistant prostate cancer: A network meta-analysis.
    Song P; Huang C; Wang Y
    Int J Surg; 2018 Aug; 56():133-140. PubMed ID: 29906643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
    Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
    J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.
    Francini E; Petrioli R; Rossi G; Laera L; Roviello G
    Tumour Biol; 2014 Nov; 35(11):10601-7. PubMed ID: 25195134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and toxicity of molecular targeted therapies in combination with docetaxel for metastatic castration-resistant prostate cancer: a meta-analysis of phase III randomized controlled trials.
    Qi WX; Fu S; Zhang Q; Guo XM
    J Chemother; 2015 Jun; 27(3):181-7. PubMed ID: 25492160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.
    Qi WX; Shen Z; Yao Y
    J Cancer Res Clin Oncol; 2011 Dec; 137(12):1785-90. PubMed ID: 21915752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
    Petrelli F; Barni S
    Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
    Feyerabend S; Saad F; Li T; Ito T; Diels J; Van Sanden S; De Porre P; Roiz J; Abogunrin S; Koufopoulou M; Fizazi K
    Eur J Cancer; 2018 Nov; 103():78-87. PubMed ID: 30218976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: Multicenter validation in patients from the Chinese Prostate Cancer Consortium.
    Pei X; Wu K; Sun Y; Gao X; Gou X; Xu J; Gao F; He D; Li L;
    Urol Oncol; 2020 Jan; 38(1):2.e11-2.e17. PubMed ID: 31672485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
    Bryce AH; Chen YH; Liu G; Carducci MA; Jarrard DM; Garcia JA; Dreicer R; Hussain M; Eisenberger MA; Plimack ER; Vogelzang NJ; DiPaola RS; Harshman L; Sweeney CJ
    Eur Urol Oncol; 2020 Dec; 3(6):717-724. PubMed ID: 32807727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
    Llovet JM; Montal R; Villanueva A
    J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance).
    Aggarwal R; Halabi S; Kelly WK; George D; Mahoney JF; Millard F; Stadler WM; Morris MJ; Kantoff P; Monk JP; Carducci M; Small EJ;
    Cancer; 2013 Oct; 119(20):3636-43. PubMed ID: 23913744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
    Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
    Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.